A Phase I study of BVX-0918A in Stage III/Stage IV Ovarian Cancer
Latest Information Update: 13 Jun 2022
At a glance
- Drugs BVX-0918A (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- Sponsors BioVaxys
- 08 Jun 2022 According to a BioVaxys media release, BioVaxys President and Chief Operating Officer Kenneth Kovan stated that completion of OVCAR-3 cell banks is another step towards our ability to produce GMP yields of BVX-0918, and brings the company closer to this Phase I study in the EU planned for later this year.
- 01 Jun 2021 According to a BioVaxys media release, first phase of bioproduction has been begun,w construction of a new GMP clean room facility needed for producing clinical supply of BVX-0918.Bio Elpida will work with BioVaxys to prepare the manufacturing section of the CTA for the EU. Upon acceptance of the CTA, the second phase of the engagement would then commence, which is the manufacturing and testing of clinical samples for administration to patient for this trial.
- 01 Jun 2021 According to a BioVaxys media release, this trial is planned for Q2 next year.